Research & publications
Original research is at the heart of what we do. For more than 60 years, our experts have published across a wide range of topics from the fundamentals of health economics itself to the challenges facing health care in the UK and internationally.
The latest research and publications
The commercial case for investing in ALS
Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive neurodegenerative disease with devastating clinical and economic consequences.
Achieving Accelerated Patient Access to Cancer Care in Europe
In recent years, the European Medicines Agency (EMA) has introduced several accelerated pathways (APs) to enable earlier access to promising therapies where there is high unmet medical need, particularly in oncology.
Patient preferences for treatment in relapsed/refractory acute leukemia
When acute leukemia relapses, treatment decisions can be complex. Patients may face trade-offs between survival benefits, side effects and how treatment is delivered. This study asked people with acute leukemia across five countries what matters most to them when making these choices.
Patient preferences for treatment in relapsed/refractory acute leukemia
When acute leukemia relapses, treatment decisions can be complex. Patients may…
The value of cell and gene therapies to the UK economy
Cell and gene therapies (CGTs) are moving rapidly from specialist trials to…
The broader economic benefits of COVID-19 vaccination
Why investigating the economic case for ongoing COVID-19 vaccination matters…
Understanding the preferences of people with acute leukemia for different health outcomes
When we want to understand or measure someone’s “health-related…
Taking STRIDES: The value of diagnostics against AMR
Addressing a critical gap in AMR policy and evaluation Antimicrobial resistance…
Altering the trajectory of HIV in Europe
Despite substantial medical advancements that have transformed HIV into a…
Understanding the Full Value of Long-Acting Therapies: less is more?
Long-acting (LA) therapies represent a significant innovation in pharmaceutical…
An Analysis of NICE’s Optimised Decisions from 2015 to 2024
The National Institute for Health and Care Excellence (NICE) is the body…
Analysing Global Immunisation Expenditure
Immunisation programmes are foundational to public health. Organised by health…
The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region
Health Technology Assessment (HTA) agencies evaluate and make decisions on the…